Luo J C, Zehab R, Anttila S, Ridanpaa M, Husgafvel-Pursiainen K, Vainio H, Carney W, De Vivo I, Milling C, Brandt-Rauf P W
Department of Medicine and Comprehensive Cancer Center, Columbia University, New York, NY 10032.
J Occup Med. 1994 Feb;36(2):155-60. doi: 10.1097/00043764-199402000-00010.
Serum levels of p53 protein were examined in 23 cases of lung cancer (many with potential asbestos exposure), 23 unexposed matched hospital control subjects, 58 unmatched general population control subjects, and 4 people with nonmalignant lung disease using an enzyme-linked immunosorbent assay and Western immunoblotting. Average levels of serum p53 in the lung cancer patients (0.55 ng/mL) were higher than in the cases of nonmalignant lung disease (0.42 ng/mL) or in the matched (0.32 ng/mL) or unmatched (0.31 ng/mL) control subjects, but the differences were not statistically significant. However, three of the cases of lung cancer (13%) were found to have serum p53 levels much greater than those of the control subjects (> 2 SD above the mean) and to have confirmatory positive Western blots for p53. The tumors from these subjects demonstrated increased levels of p53 in the tissue by immunohistochemistry and/or the presence of mutations in the p53 gene. These results suggest that p53 protein can be detected in serum in a portion of lung cancer cases with p53 alterations in the tumor tissue.
采用酶联免疫吸附测定法和蛋白质免疫印迹法，对23例肺癌患者（其中许多人可能接触过石棉）、23名未接触石棉的配对医院对照者、58名非配对的普通人群对照者以及4名患有非恶性肺病的患者的血清p53蛋白水平进行了检测。肺癌患者血清p53的平均水平（0.55 ng/mL）高于非恶性肺病患者（0.42 ng/mL）或配对对照者（0.32 ng/mL）及非配对对照者（0.31 ng/mL），但差异无统计学意义。然而，发现3例肺癌患者（13%）血清p53水平远高于对照者（高于平均值2个标准差以上），且蛋白质免疫印迹法证实p53呈阳性。这些患者的肿瘤经免疫组织化学检测显示组织中p53水平升高和/或p53基因存在突变。这些结果表明，在一部分肿瘤组织中p53发生改变的肺癌病例中，血清中可检测到p53蛋白。
